What's New in Dyslipidemia?

Overview

LDL-C vs CV Events Secondary Prevention Studies

High- vs Low-Dose Statin

The Statin Hypothesis Low vs High Dose

LDL-C Level vs Statin Intensity

Lipoprotein Abnormalities in T2D

Lipoprotein Abnormalities in T2D (cont)

T2D as a CVD Risk Equivalent

The Role of Statins 2013 ACC/AHA Guidelines

2013 ACC/AHA Cholesterol Guidelines 4 Statin Benefit Groups Identified

2014 NLA Criteria for Treatment Initiation According to Risk

2016 Consensus Statement From ACC/AHA and NLA

Intensity of Statin Treatment

Role of Metabolic Syndrome

Statin Nonadherence and Intolerance

Statin Discontinuation After ACS Clinical Consequences

Statin Discontinuation in RCTs

Statin Adherence in Registry Databases

Keep in Mind…

Issues With Recommendations Based on Statin Intensity

Approaches to Lipid Treatment in T2D 2016 AACE/ACE Algorithm

Role of PCSK9 Inhibitors

ODYSSEY LONG TERM Alirocumab 150 mg vs Placebo 2:1

ODYSSEY LONG TERM (cont)

OSLER Evolocumab + Standard Therapy vs Standard Therapy Alone 2:1

ODYSSEY LONG TERM AEs by Achieved LDL-C

GAUSS-2 and ODYSSEY ALTERNATIVE PCSK9 Inhibitors Well Tolerated by Statin-intolerant Patients

Incorporating PCSK9 Inhibitors Into Endocrinology Practice

Abbreviations

Abbreviations (cont)

Abbreviations (cont)